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a b s t r a c t
Introduction: Aluminum phosphide (AlP) poisoning has a high mortality rate despite inten-
sive care management, primarily because it causes severe myocardial depression and severe
acute respiratory distress syndrome. The purpose of this study was to evaluate the impact of
the novel use of extracorporeal membrane oxygenation (ECMO), a modiﬁed ‘‘heart-lung’’
machine, in a speciﬁc subset of AlP poisoning patients who had profound myocardial
dysfunction along with either severe metabolic acidosis and/or refractory cardiogenic shock.
Methods: Between January 2011 and September 2014, 83 patients with AlP poisoning were
enrolled in this study; 45 patients were classiﬁed as high risk. The outcome of the patients
who received ECMO (n = 15) was compared with that of patients who received conventional
treatment (n = 30).
Results: In the high-risk group (n = 45), the mortality rate was signiﬁcantly (p < 0.001) lower
in patients who received ECMO (33.3%) compared to those who received conventional
treatment (86.7%). Compared with the conventional group, the average hospital stay was
longer in the ECMO group (p < 0.0001). In the ECMO group, non-survivors had a signiﬁcantly
(p = 0.01) lower baseline LV ejection fraction (EF) and a signiﬁcantly longer delay in presen-
tation (p = 0.01).
Conclusion: Veno-arterial ECMO has been shown to improve the short-term survival of
patients with AlP poisoning having severe LV myocardial dysfunction. A low baseline LVEF
and longer delay in hospital presentation were found to be predictors of mortality even after
ECMO usage. Large, adequately controlled and standardized trials with long-term follow-up
must be performed to conﬁrm these ﬁndings.
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Pesticide poisoning is a worldwide health problem that can
occur intentionally for suicidal or homicidal purpose and
unintentionally as the result of accidental or occupational
causes. Furthermore, self-poisoning accounts for one-third of
suicides throughout the world.1 Aluminum phosphide (AlP) is
a solid fumigant that is used for the fumigation of agricultural
compounds, in animal feed, and for pest control in agricultural
ﬁelds. In North India, AlP poisoning has been found to be the
most common cause of suicidal death.2 In India, the
considerable time gap between the ingestion of the poison
and the initiation of proper treatment has been found to be the
major reason for the high mortality rate of AlP poisoning. AlP
poisoning mortality rates vary from 40% to 80%.3 Once
refractory myocardial depression sets in, which is
not uncommon, the mortality rate further increases to 77%
(37–100%).3,4 Reports in the literature have shown that
resistant hypotension and metabolic acidosis are robust
predictors of a poor prognosis after AlP poisoning.5 Extracor-
poreal membrane oxygenation (ECMO) is a well documented
therapy for improving survival in patients with severe
respiratory failure.6 Veno-venous ECMO is the preferred
method in patients with isolated respiratory failure.6 However,
veno-arterial (VA) ECMO should be used in patients with
combined cardio-vascular and respiratory failure.
In this study, we investigated the use of VA ECMO in a high-
risk subgroup of AlP poisoning patients who were at a very risk
of mortality with AlP poisoning. The high risk subgroup was
identiﬁed by following two criteria: (1) severely reduced left
ventricular ejection fraction (LVEF ≤ 35%) and (2) severe
metabolic acidosis (pH ≤ 7.0) and/or refractory shock, i.e.




This was a tertiary care, single-center prospective study. We
enrolled 83 patients admitted to our center with AlP poisoning
between January 2011 and September 2014. All patients had
ingestion of the tablet form of AlP with suicidal intention.
Forty-ﬁve patients were classiﬁed as high-risk group of AlP
poisoning. The patients of AlP poisoning were classiﬁed as a
high risk if they met the following criteria:
1. Left ventricular myocardial dysfunction i.e. EF of ≤35%
2. Severe metabolic acidosis (pH ≤ 7.0) and/or refractory shock
i.e. systolic blood pressure <80 mmHg despite conventional
medical therapies.
All 45 patients were given the option for ECMO but
30 patients refused primarily due to economical issues.
Thereby, 30 patients received the conventional mode of
treatment (conventional group) while 15 patients received
ECMO in addition to conventional treatment (ECMO group).
The outcome of patients in the high-risk group that weretreated with ECMO and those of patients in the conventional
treatment group was compared. Fig. 1 demonstrates the study
design. Conventional treatment for AlP poisoning included
gastric lavage with coconut oil, early resuscitation with ﬂuid
and vasoactive agent, intravenous magnesium sulfate, and
intensive care management. Various vasoactive agents in-
cluded dopamine, epinephrine, and nor-epinepherine. Intra-
aortic balloon pumping was not used as a cardiac support in
any of the patient. All patients in ECMO group and majority of
the patients in conventional group received ventilator support
at the time of admission or during the course of hospitaliza-
tion.
2.2. ECMO indications and procedure
VA ECMO was considered for patients with AlP poisoning who
were classiﬁed as high-risk group as mentioned above.
The cannulation site was determined based on patient
status. The majority of patients underwent percutaneous
cannulation through femoral vessels. The ECMO cannulation
was done in intensive care unit. A venous cannula was placed
in the inferior vena cava or right atrium for drainage infusion.
The usual size of venous cannula ranges from 21 to 25 F. The
return cannula is a short arterial cannula inserted via
the common femoral artery. This cannula is fully inserted to
the taper, with the tip lying in the common iliac artery or lower
aorta. The usual size of arterial cannula ranges from 17 to 21 F.
Additional distal perfusion 9 F return cannula (‘‘backﬂow
cannula’’) is inserted antegradely into the common femoral
artery and directed into the superﬁcial femoral artery.
The patients were maintained on a continuous heparin
infusion to achieve an activated clotting time between 180 and
200 s. The goal for the activated clotting time was adjusted if
there were issues with bleeding or coagulation. To maintain a
hemoglobin level of ≥10 g/dL and a platelet count of
≥100,000 dL–1, patients received a transfusion during the
ECMO treatment. The patients were continuously monitored
in terms of hemodynamic improvement, reversal of metabolic
acidosis, and adequate oxygenation. Once these parameters
are satisfactory, the ECMO weaning protocols were initiated.
The circuit ﬂow was reduced to assess the native cardiac
function in the setting of an increased venous return. Flow was
reduced from 2.5 L/min in a series of 0.5 L/min increments
while hemodynamic and echocardiographic evaluations were
done. Decannulation was performed once the patient had
improvement in LVEF to >35%, maintaining systolic
blood pressure of >90 mmHg without any inotropic support
and acidosis had recovered.
2.3. Statistical analysis
Continuous variables are presented as the mean  standard
deviations. Categorical variables are expressed as percentages.
Continuous variables were compared using Student's t test if
the data followed a normal distribution and using the
Wilcoxon test if the data were skewed. Categorical variables
were compared using the chi-square test or Fisher's exact test
as indicated. All probability values were 2-sided, and differ-
ence with p values of <0.05 was considered statistically
signiﬁcant.
Fig. 1 – Flow chart showing the study design. ALP: aluminum phosphide, ECMO: extracorporeal membrane oxygenation. *
Patients were categorized in high risk group if the met the following criteria: (1) Left ventricular myocardial dysfunction i.e.
ejection fraction of ≤35%. (2) Severe metabolic acidosis (pH ≤ 7.0) and/or refractory shock i.e. systolic blood pressure
<80 mmHg despite conventional medical therapies.
Table 1 – Baseline characteristics of patients in high-risk








Age (in years) 29.1  12.7 34  8.9 0.03
Sex (male) 18 (60%) 11 (73.3%) 0.37
Average delay in
presentation (in hours)
7.6  5 8.9  3.4 0.06
Number of tablets of
Aluminum phosphide
2.1  1.5 2.1  0.9 0.43
Heart rate at the time of
presentation >100 bpm
16 (53.3%) 15 (100%) –
Systolic blood pressure
at the time of
presentation
<90 mmHg
22 (73.3%) 15 (100%) –
Patients with GFR
<60 ml/min
13 (43.3%) 8 (53.3%) 0.52
ECG abnormality 10 (33.3%) 12 (80%) 0.01
ECMO: extracorporeal membrane oxygenation.
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Detailed information regarding the occurrence of adverse
events and any related symptoms was obtained during routine
follow-up at 30 days and 6 months from the time of procedure.
Patients were either interviewed by phone or seen by their
physician. Those with signiﬁcant complaints like dyspnea,
fatigue, pedal edema, etc. underwent complete clinical,
electrocardiographic, and laboratory examinations.
3. Results
Between January 2011 and September 2014, 45 of 83 patients
with AlP poisoning at our center were classiﬁed as high risk as
mentioned above. In this high-risk group, 15 patients received
ECMO as a therapeutic modality along with standard manage-
ment, while 30 patients received conventional management.
3.1. Baseline characteristics
The mean age of the ECMO group was 34  8.9 years (73.3%
male), while the mean age of the conventional group was 29.1
 12.7 years (60% males). The ECMO group was signiﬁcantly
older than the conventional group. The clinical characteristics
of both groups are listed in Table 1.
Among AlP poisoning patients in the high-risk subgroup,
the mortality rate was signiﬁcantly lower in those treated withECMO. The in-hospital mortality rate was 86.7% (n = 26) in the
conventional group and 33.3% (n = 5) in the ECMO group
(p value 0.001). The average delay in reaching the hospital after
exposure to AlP was higher, although not signiﬁcant, in the











6.8  10 16.1  12.9 <0.0001
pH <7.0 8 (26.7%) 15 (100%) –
LVEF (%) 27.2  4.0 27.1  2.9 0.7
Systolic blood
pressure (<90 mmHg)
22 15 (100%) –
In-hospital mortality 86.7% (26) 33.3% (5) 0.001
ECMO: extracorporeal membrane oxygenation.
Table 3 – Demonstrating the temporal trends in im-











At the time of discharge 50.5  2.4 50  2.1 0.7
At six months of follow up 60.8  1.7 62  2.4 0.3
LVEF: left ventricular ejection fraction; ECMO: extracorporeal
membrane oxygenation.








LVEF at admission (%) 26.2  4.8 19.6  1.7 0.01
Delay in presentation
(hours)
7.3  2.6 12.0  2.6 0.01
Hospital stay (days) 22.8  10.3 2.6  0.5 0.002
Poison exposure to
ECMO (hours)
10.8  4.2 15.8  3.1 0.01
Admission to ECMO
(hours)
3.5  3.2 3.8  0.8 0.2
Duration of ECMO
(hours)
60  35 62.4  13.1 0.1
LVEF: left ventricular ejection fraction; ECMO: extracorporeal
membrane oxygenation.
Table 5 – Demonstrating the complications related to
ECMO usage.
Complication related to ECMO use
Vascular access
site haematomas
53.3% (n = 8)
Need for vascular access
site surgical correction
20% (n = 3)
Persistent thrombocytopenia
(<50,000 mm3)
66.7% (n = 10)
Worsening of renal failure 60% (n = 9)
ECMO: extracorporeal membrane oxygenation.
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average hospital stay was signiﬁcantly longer in the ECMO
group (p < 0.0001). Table 2 demonstrates the results from this
study. Among the survivors, the hospital stay in ECMO group
(22.8  12.3 days) was signiﬁcantly longer than the conven-
tional group (9.8  4.5 days) with p-value of 0.02. No mortality
was noted at six months of follow-up. Among the survivors,
there was signiﬁcant improvement in LVEF during the hospital
stay. At the time of discharge, the mean LVEF was 50.5  2.4%
and 50  2.1% in the conventional and ECMO groups, respec-
tively. At the 6-month follow-up, LV function had completely
normalized, with average LVEF of 60.8  1.7% and 62  2.4% in
the conventional and ECMO groups, respectively. Table 3
shows the temporal trends in improvement of LV functions
among survivors.
In the ECMO group, the baseline LVEF obtained at
admission was signiﬁcantly lower in non-survivors (19.6
 1.7%) than survivors (26.2  4.8%) with p-value of <0.01. In
the ECMO group, the average delay in the initiation of ECMO
treatment after hospital admission was 3.6  2.6 h, and this
delay was similar between survivors and non-survivors. The
duration of ECMO usage during the hospital stay was similar
between the non-survivors (62.4  13.1 h) and survivors
(60  35 h) with the p-value of 0.1. Table 4 shows a comparison
between the survivors and non-survivors in the ECMO group.
Two patients died within 3 days of admission, both of
whom had multi-organ dysfunction prior to initiation of
ECMO. Three patients succumbed to disseminated intravas-
cular coagulopathy and acute renal failure. All of these ﬁve
patients received ECMO in addition to conventional treatment.
Vascular access site haematomas were found the major
complication in the ECMO group and was seen in 53% (n = 8) ofcases, and in three patients, this complication necessitated
surgical correction. Limb ischemia was not observed in those
who received ECMO. Another observed complication was
persistent thrombocytopenia (<50,000 mm3) that required
multiple platelet transfusions. Sudden worsening of renal
function was noted in 60% (n = 9) of patients, and six of those
patients required continuous renal replacement therapy
(CRRT). Lung injury was not observed in any of the patients
in either group. Table 5 highlights the complications related to
ECMO use.
4. Discussion
AlP is an insecticide that is commonly used in developing
countries, including the Indian subcontinent. The mortality
rate of AlP poisoning is approximately 70%.3 After exposure
to hydrochloric acid and water in the stomach, AlP releases
phosphine gas, which is rapidly absorbed gastro-intestinal
contact. Each tablet of AlP weighs about 3 g and contains
two compounds: AlP and aluminum carbonate in a ratio of
54:46. Each 3 g tablet releases 1 g of phosphine gas. The LD50
dose of AlP is 10 mg/kg of body weight. The speciﬁed fatal
dose is 0.15–0.5 g. However, most of the patients present
with ingestion of three or more tablets, which invariably
results in death.
Phosphine gas causes the release of oxidant-free radicals
and the inhibition of metabolic enzymes, such as mitochon-
drial cytochrome C oxidase, and thereby interferes with
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conformational changes to mitochondria and a 70% reduction
in oxidative respiration. These effects cause a signiﬁcant
decrease in mitochondrial membrane potential.8
Other pathogenic mechanisms of AlP poisoning include the
following:
1. Generation of highly reactive hydroxyl radicals due to the
interaction between phosphine and hydrogen peroxide.
2. Inhibition of catalase and peroxidase enzymes by phos-
phine.
Both the above-mentioned mechanisms result in lipid
peroxidation due to the production of reactive hydroxyl
radicals.9–11 Post-mortem studies have suggested a strong
correlation between increased levels of superoxide dismut-
ase, malonyldialdehyde, and catalase and mortality. Exces-
sive oxidative stress results in an increase in glutathione
reduction and, thus, a decrease in glutathione concentration
in various tissues; this results in cellular injury because
glutathione is a protective factor against oxidation that acts
by catalyzing the reduction of oxygen peroxide into oxygen
and water.12
Cardiac myocytes are directly injured by the toxic effects of
phosphine gas and as a result of the profound circulatory
collapse that occurs secondary to excessive ﬂuid loss and
adrenal gland damage in cases of AlP poisoning.13 Major
pathological changes observed in muscle biopsy of non-
survivor patients include myocyte vacuolation, areas of
myocytolysis and myocyte degeneration.14
The presentation of AlP poisoning depends on the amount
of toxin ingested, its route of entry, and the duration between
exposure to the poison and hospital admission. In this study,
the average delays in hospital admission after AlP exposure
were 7.6  5 h and 8.9  3.4 h in the conventional and ECMO
groups, respectively. Patients with severe inhalation toxicity
may develop acute respiratory distress syndrome, cardiac
complications (e.g. heart failure and dysrhythmias), and
neurological complications (e.g., convulsion and coma);
furthermore, late manifestations of hepatotoxicity and
nephrotoxicity can also occur.15–17 Both hypo- and hyper-
magnesaemia can occur in cases of AlP poisoning, although
their mechanism of action is not clear.18 In our study, all
patients had hypomagnesaemia. Other uncommon compli-
cations of AlP poisoning include intravascular hemolysis,
acute adrenocortical insufﬁciency, hepatitis, pancreatitis,
hypo- or hyperglycemia, meth-hemoglobinemia, microan-
giopathic hemolytic anemia, and disseminated intravascu-
lar coagulation.13,19 In our study, four patients experienced
acute renal failure, two of whom were placed on CRRT.
Clinically, cardiac complications of AlP poisoning are
secondary to phosphine-induced myocardial damage; acute
cardiovascular collapse is the most common presentation of
AlP poisoning (60–100% of cases).20 Bhasin et al.21 demonstrat-
ed a similar pattern of global hypokinesia of the LV walls in
80% of their cases. Non-speciﬁc ST-T wave changes and intra-
ventricular conduction defects are commonly observed on
electrocardiograms (ECGs) of AlP poisoning patients and are
most likely due to focal myocardial necrosis and changes in
membrane action potentials.22There is no speciﬁc antidote for phosphine or metal
phosphide poisoning. Many different modalities have been
used to treat AlP poisoning with varying degrees of success,
including magnesium sulfate, N-acetyl cysteine, and decon-
tamination with vegetable oils.13 None of these agents have
been shown to decrease mortality or have signiﬁcant impacts
on patient outcomes, but they may be used in addition to
cardiovascular support. The majority of patients die despite
intensive medical care. Aggressive support remains the
management of choice for AlP poisoning. Similar to other
poisons, AlP has a deﬁnite elimination time; therefore early
arrival, resuscitation and intensive supportive therapy can
result in a good outcome. Notably, the half-life of phosphine
gas is 5–24 h, depending on various factors.23
The mortality rate of AlP poisoning is highly variable,
ranging from 37% to 100% and can reach more than 60% even
in patients treated by experienced clinicians at well-equipped
hospitals.24 Singh et al.25 and Bogle et al.4 showed that the
outcome of these patients is primarily determined by the
presence or absence of severe resistant hypotension and
metabolic acidosis.
Because the AlP poisoning causes reversible myocardial
depression and lung injury/ARDS, and does not tend to have
major effects on smooth muscle vasculature, VA-ECMO was
used as a bridge therapy in this subset of patients. Various
other temporary percutaneous support devices being used in
cardiogenic shocks from other causes include tandem heart,
intra-aortic balloon support (IABP), Impella, etc. IABP had
been used in AlP-related cardiogenic shock in few anecdotal
case reports. VA-ECMO takes deoxygenated blood from a
central vein or the right atrium, pumps it through an
oxygenator, and then returns the oxygenated blood, under
pressure, to the arterial side of circulation (typically to the
aorta). This form of ECMO partially supports CO because the
ﬂow through the ECMO circuit is in addition to normal CO.
ECMO is a complex, risky, and expensive life support measure
that is usually reserved for patients whose underlying disease
process is associated with a mortality rate >80% and is not
responding to conventional ventilatory support or medical
therapies but is still potentially reversible.26 ECMO has rapidly
gained importance as a support measure for both cardio-
vascular failure and acute respiratory distress.27 Although
ECMO is a candidate therapy for life-threatening cardio-
respiratory failure, it has never been implemented in cases of
AlP-induced severe myocardial dysfunction with hemody-
namic and respiratory compromise. Our institutional experi-
ence of over ten years suggests that in patients with AlP
poisoning, presenting late to the emergency department with
severe LV dysfunction and resistant hypotension or severe
metabolic acidosis, regardless of the provision of inotropic
support for circulatory failure and ventilatory support for
respiratory failure, the mortality rate is almost 100%. So, VA-
ECMO seems to be a promising modality as a cardio-
respiratory assist device in AlP poisoning.
In our study, in addition to conventional and supportive
care, treatment with ECMO reduced the in-hospital mortality
of AlP poisoning from 86.7% to 33.3% (p = 0.001). At the time of
discharge, all patients in both groups had nearly normal LV
myocardial function and this was found to have completely
normalized at follow-up. This result suggests that the
i n d i a n h e a r t j o u r n a l 6 8 ( 2 0 1 6 ) 2 9 5 – 3 0 1300myocardial dysfunction secondary to the AlP poisoning is
reversible. Elabbassi et al.28 demonstrated a similar ﬁnding of
reversible myocardial dysfunction in his case report. Average
duration of ECMO support was 60  35 h among the survivors
and the half life of phosphine gas is 5–24 h as mentioned
above, thereby suggesting that the cardio-respiratory failure is
temporary and correlates with the half life of phosphine gas
effect.
Our study demonstrated that low baseline LVEF is an
important predictor of mortality in AlP poisoning patients who
receive ECMO therapy. Additionally, the length of time of the
ECMO treatment was signiﬁcantly longer in non-survivors.
Probably, the prolonged use of ECMO leads to additional
complications beyond those of AlP toxicity itself, thus further
compromising the patient.
ECMO is associated with several complications. In our
study, we encountered the following complications: vascular
access site haematomas requiring multiple blood transfu-
sions, the need for surgical correction of vascular complica-
tions, profound thrombocytopenia and acute renal failure with
or without the need for renal replacement therapy. In the
initial few cases, the vascular access site complications were
noted in almost all the patients and this was reduced in
subsequent patients. It is probably considered to be due to the
learning curve for the procedure at our institute in addition to
its emergent nature.
This study demonstrates the novel use of ECMO in the
management of a speciﬁc subset of AlP poisoning patients
with a very high risk of mortality. The use of ECMO for this
indication has been previously reported as anecdotal case
reports only.29 However, further studies with large numbers of
patients and long-term follow-up are needed.
5. Limitations
Our study had certain limitations. First, because data were
collected at a single center, the ﬁndings may not be
representative of the general population. Second, the number
of included patients was low; thus, a large prospective study is
necessary to conﬁrm our results. Third, ECMO itself is
associated with various complications, as previously dis-
cussed, that are more prevalent during the learning phase of
this procedure at an institution.
6. Conclusion
AlP poisoning carries a very high mortality rate. Venoarterial
ECMO has shown promising improvement in the short-term
survival of adults with AlP poisoning associated with LV
dysfunction and severe metabolic acidosis and/or refractory
shock. However, ECMO is also associated with signiﬁcant
complication rates, which must be incorporated into the risk–
beneﬁt analysis when determining the best treatment course.
Another important highlight is the early presentation to the
hospital and immediate referral to the tertiary care center with
facility and experience to use ECMO. The decision to start
ECMO should be prompt. Future studies may further reﬁne the
clinical criteria for its indications.What is already known?
AlP poisoning carries nearly 100% mortality if patient has
left ventricular dysfunction, shock, and severe metabolic
acidosis.
As the myocardial dysfunction associated with the AlP
poisoning is reversible, this high-risk subset of patients
with AlP poisoning might be beneﬁted by a cardio-respi-
ratory assist device (as abridge therapy) which might tide
over the crises in initial few days and thereby tend to
improve the outcome.
What this study adds?
From this study, it is evident that in high-risk subset of
AlP poisoning patients, who carry almost 100% mortality,
the use of ECMO as a cardio-respiratory assist device has
shown to signiﬁcantly improve the outcome in term of
mortality reduction.
In this study, among the high-risk group (n = 45), the
mortality rate was signiﬁcantly (p < 0.001) lower in
patients who received ECMO (33.3%) compared to those
who received conventional treatment (86.7%).
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